The Syk family tyrosine kinase ZAP-70 is essential for normal Tcell development and signaling. Recently, leukemic cells from some patients with B-cell chronic lymphocytic leukemia (B-CLL) were shown to express ZAP-70. Owing to the prognostic value of B-CLL ZAP-70 expression, this phenotype may reflect intrinsic biological differences between the two subsets of disease. However, it remains unclear whether CLL-B cells aberrantly acquire ZAP-70 expression during the transformation process or whether ZAP-70 may be expressed under certain conditions in normal human B-lymphocytes. To discriminate between these two possibilities, we assessed ZAP-70 expression in normal human B-lymphocytes. Our data demonstrate that ZAP-70 is expressed in a subpopulation of tonsillar and splenic normal B-lymphocytes that express an activated phenotype. Furthermore, ZAP-70 expression can be induced in vitro upon stimulation of blood and tonsillar B cells. Finally, we show that phosphorylation of ZAP-70 occurs in tonsillar B cells with stimulation through the B-cell receptor. These results provide new insight into normal human B-cell biology as well as provide clues about the transformed cell in B-CLL.
Introduction
Syk family protein tyrosine kinases are essential for normal Band T-lymphocyte development and for B-(BCR) and T-cell receptor signaling. In this regard, the tyrosine kinase, ZAP-70, is crucial for T-cell development and T-cell receptor signal transduction, whereas Syk plays a comparable role in B-cell development and BCR signaling (reviewed in van Oers and Weiss 1 ). ZAP-70 expression has been reported to be present in T cells and NK cells, 2, 3 but not in B cells. However, recent studies focusing on B-cell chronic lymphocytic leukemia (B-CLL) suggest that ZAP-70 may be specifically expressed in leukemic B cells expressing a BCR that has not acquired somatic mutations. [4] [5] [6] [7] [8] [9] As unmutated immunoglobulin variable heavychain (Ig V H ) region gene status in B-CLL is associated with more advanced clinical stage and progressive disease, [10] [11] [12] [13] ZAP-70 expression has prognostic value. [4] [5] [6] [7] 9, 14 The precise mechanisms underlying the link between these factors and disease outcome, however, remain largely unknown. For example, it remains unclear whether CLL-B cells aberrantly activate the expression of the ZAP-70 gene during the transformation process or whether instead ZAP-70 may be expressed in normal B-lymphocytes in a subset-specific or activation-related manner.
Initial studies determined that ZAP-70 was expressed in T cells and NK cells but not in B cells. 2, 3 Chan et al 2 did detect very low levels of ZAP-70 mRNA in the spleen; however, isolated B cells appeared to lack detectable expression of ZAP-70 protein. 3 Of note, the latter studies were restricted to peripheral blood B cells. In contrast, Schweighoffer et al 15 demonstrated that ZAP-70 expression could be detected in pro-B, pre-B, and mature murine B cells using sensitive and specific antibodies to this Src kinase. These authors noted that B-cell expression of ZAP-70 was five to 10 times less than that observed in thymocytes. Relevant to the work described in this report, it is important to note that total splenic cells were examined suggesting the possibility that B-cell ZAP-70 expression may vary among B-cell subpopulations. In addition, these investigators also demonstrated that ZAP-70 was activated by the pre-BCR and plays a role in murine B-lymphocyte development by partially compensating for Syk in the pro-B to pre-B transition. Furthermore, Meade et al 16 demonstrated in a murine model that Syk is dispensable for negative selection of B cells and they speculated that ZAP-70 may be compensating in a redundant role. This is consistent with studies in B-CLL demonstrating that ZAP-70 þ leukemic cells exhibit increased tyrosine phosphorylation of cytosolic proteins with BCR ligation. 17, 18 Although a thorough analysis of ZAP-70 expression in human B cells has not yet been performed, there is limited evidence that ZAP-70 is expressed at the mRNA level 5, 8 and protein level in some human B-cell lines 19 and at the protein level in a very minor population of normal blood B cells. 5 In contrast, Dü rig et al 14 failed to see evidence of ZAP-70 mRNA expression in normal CD19 þ blood B cells; however, data from only one normal individual were included in this report. Collectively, these data suggest the possibility that ZAP-70 may be involved in normal human B-lymphocyte activation.
The studies described in this report were therefore designed to rigorously examine ZAP-70 expression in normal human B-lymphocytes. In the present study, we present evidence that a subset of freshly isolated B cells from spleen and tonsil, but not peripheral blood, indeed express ZAP-70 at levels comparable to that observed in T cells. In addition, we present provocative data that ZAP-70 expression may correlate with the state of B-cell activation and/or differentiation.
Materials and methods

Cell isolation and polyclonal stimulation
Peripheral blood mononuclear cells were isolated from buffy coats from normal blood donors using CD19 magnetic beads (Stemsep, Vancouver, BC, Canada) as described previously. 20 Tonsillar and splenic B cells were isolated from mononuclear cells obtained from discarded surgical tissue using similar methodology. B cells were polyclonally activated in culture for 3 days using either 0.5 mg/ml CD40L (Alexis USA, San Diego, CA, USA) with 1 ng/ml Enhancer for Ligands (Alexis) and 50 ng/ ml IL-4, 50 ng/ml IL-10, and 30 ng/ml IL-6 (all from PeproTech; Rocky Hill, NJ), or 10 ng/ml IL-15 (Peprotech) and 10 mg/ml CpG oligodeoxynucleotides (CpG ODN 2006), as described previously. 21 
Western blot analysis
Isolated cells were lysed on ice in 1% Brij lysis buffer plus protease and phosphatase inhibitors, 22 boiled for 5 min, electrophoresed, and transferred to Immobilon-P membranes as described previously. 20 BCR stimulation was performed by stimulating 50 Â 10 6 purified B cells on ice with 10 mg/ml of a biotinylated F(ab 0 ) 2 goat anti-human IgM-, IgG-, and IgA-specific antibody (Biosource International, Camarilla, CA, USA). The cells were then pelleted and resuspended in 20 mg/ml avidin (Sigma, St Louis, MO, USA) in 200 ml RPMI, incubated at 371C for 0.5, 1, 5, 10, or 15 min, and then lysed in 1 ml of 1% Brij lysis buffer with inhibitors and rotated for 1 h at 41C with 2 mg of anti-ZAP antibody (Upstate, Lake Placid, NY, USA). Proteins were purified using 25 ml of anti-mouse IgG agarose (Sigma). Beads were then washed twice with 1% Brij lysis buffer and inhibitors, boiled, electrophoresed, and transferred as described above. Membranes were blocked with 2% bovine serum albumin in TBS-0.2% Tween (25 mM Tris-HCl (pH 7.2), 150 mM NaCl, 0.2% Tween) for 1 h. ZAP-70 was detected using an anti-human ZAP-70 mAb at a 1:1000 dilution. Phosphorylated protein was detected using the phosphotyrosine antibody, clone 4G10 (Upstate) at a dilution of 1:10 000. Syk levels were detected using anti-human Syk mAb (Santa Cruz, CA) at a 1:1000 dilution. b-actin levels were determined using an antihuman b-actin mAb (Novus, Littleton, CO, USA) at a 1:5000 dilution. The secondary antibody used was HRP-conjugated polyclonal anti-mouse IgG (Amersham, Piscataway, NJ). Immunoreactive proteins were detected using an enhanced chemiluminescence detection system (SuperSignal, Pierce, Rockford, IL, USA). ZAP-70 levels relative to b-actin were determined using an Ambis Radioanalyitic Imaging System (Ambis Inc., San Diego, CA, USA).
Cytoplasmic staining and FACS analysis
Cells were suspended in 100 ml DPBS/2% fetal bovine serum (FBS)/1% normal mouse serum (NMS) and incubated for 25 min on ice with 10 ml APC-conjugated anti-human CD19 mAb and 10 ml PE-conjugated anti-human CD3 mAb (both from BD PharMingen, San Jose, CA, USA). Similar methods were used when staining for CD38, IgM, CD5, and CD27 (all from BD PharMingen). Cells were permeabilized using the Caltag Fixation and Permeabilization kit (Caltag, Burlingame, CA, USA). Externally stained cells were suspended in 100 ml Medium A for 15 min and washed with PBS, suspended in 100 ml Medium B for 15 min and washed with PBS, resuspended in 100 ml of DPBS/2%FBS/1%NMS, and incubated with 2 ml AlexaFluor 488-conjugated anti-human ZAP-70 mAb (Caltag) for 15 min. Cells were then given two final washes with DPBS/ 2%FBS and fixed with 1% paraformaldehyde. Cells were analyzed on a FACSCAN flow cytometer (Becton Dickinson, Mountain View, CA, USA). Control antibodies included mouse IgG 1 for all PE-and APC-conjugated antibodies (BD Pharmingen), and the ZAP-70 AlexaFluor 488 (Caltag). Data were analyzed using WinMDI 2.5 software.
Jurkat transfection studies
A total of 10 Â 10 6 ZAP-70-deficient p116 Jurkat T cells 23 were transfected with 30 mg of either a modified pCI control vector (Promega) or pCI vector containing a flag-tagged ZAP-70 construct or flag-tagged Syk construct. Constructs were generously provided by Dr Dan Billadeau, Mayo Clinic. The cells were electroporated at 315 V for 10 ms in 400 ml of the media. The cells were then allowed to recover for 24 h in 10 ml of complete media before being lysed for immunoprecipitation using anti-flag (Sigma) or anti-ZAP-70 mAbs.
Results
ZAP-70-expressing B cells are found in both tonsil and spleen
In order to initially determine if normal B cells express ZAP-70, B cells were isolated from peripheral blood, tonsil, and spleen and analyzed by immunoblot for ZAP-70 expression levels relative to those expressed in T cells. ZAP-70 expression was clearly detected in B cells isolated from all three anatomic sites, albeit at levels considerably lower than those expressed by primary blood T cells. However, expression of ZAP-70 between the B-cell lysates varied considerably (Figure 1a ) with tonsillar and splenic B-cell lysates exhibiting approximately two to three times the level of ZAP-70 compared to peripheral blood B cells. We have also determined that the NALM6 pre-B-cell line expresses ZAP-70 at high levels when compared to Jurkat T cells, whereas the mature B-cell line, Raji, does not express ZAP-70 (Figure 1b) . The NALM6 pre-B-cell line has been characterized as expressing only cytoplasmic IgM without a rearranged light chain. This finding is in support of observations by Schweighoffer et al, 15 demonstrating that the expression of ZAP-70 is involved in murine B-cell development.
As the literature suggests that ZAP-70 expression can be readily assessed using flow cytometry, 5,7,9-14 we adapted this method to assess cytoplasmic ZAP-70 expression in freshly isolated mononuclear cells from peripheral blood, spleen, and tonsil. This method is advantageous because it permits an assessment of B-cell ZAP-70 expression relative to T-cell expression levels and permits determination of whether all B cells express ZAP-70 at low levels, or alternatively, if there are truly ZAP-70 þ B cells that express the protein at levels comparable to that of T cells. Thus, we used a three-color flow cytometry method that permitted analysis of ZAP-70 expression in CD19 þ vs CD3 þ lymphocytes. Gating of cells is demonstrated in Figure 1c , where only CD3 þ /CD19À and CD3À/CD19 þ cells are gated to eliminate the possibility of B-T cell doublets interfering in the analysis. Of interest, although peripheral blood CD19 þ cells were essentially devoid of ZAP-70 expression (Figure 1d ), there was a subset of CD19 þ ZAP-70 þ tonsillar (3.4%; Figure 1e ) and splenic (2.3%; Figure 1f ) B cells that clearly expressed cytoplasmic ZAP-70 at levels comparable to that observed in CD3 þ CD19À mononuclear cells. The flow cytometric data are therefore consistent with the immunoblot analysis.
To determine rigorously that both methods truly detected Bcell ZAP-70 expression and did not instead reflect ZAP-70 expression contributed by contaminating T cells and NK cells or nonspecific binding, we again used immunoblotting to assess ZAP-70 levels in highly purified tonsillar and splenic B cells (Figure 2 ). It is important to note that contaminating CD3 þ T and CD56 þ NK cells in our CD19-purified B cells were routinely assessed using flow cytometry and our purification methods consistently yielded B-cell preparations that contained less than 0.5% CD3 þ and CD56 þ cells and less than 0.1% CD11b þ , CD14 þ , and CD16 þ cells. FACS analysis of a typical purification is demonstrated in Figure 2a ZAP-70 expression in B cells is not due to T-and NK cell contamination. The purified B-cell population from (a) tonsil or (c) spleen was analyzed for purity using APC-conjugated CD19 antibody and PE-conjugated CD3 and CD56 antibodies. No events were excluded. Total cell lysate (100 mg) isolated from the same purified (b) tonsillar or (d) splenic B cells was analyzed for ZAP-70 by immunoblotting (left lanes of both panels). Total cell lysate was also isolated from purified T cells, and varying amounts of lysate, expressed as a percentage of total B-cell protein ranging from 0% (no protein, lane 2) to 10%, were electrophoresed to estimate the sensitivity of this assay to T-cell contamination of the purified B cells. The values below the blot are densitometric measurements expressed as net pixel count.
ZAP-70-expressing B cells display an activated phenotype
CD38 is a known activation marker in B-lymphocytes and its expression is increased in germinal centers once a B-lymphocyte is stimulated (reviewed in Liu and Arpin 24 , Liu et al 25 ). Since ZAP-70 þ B cells were found in tonsil and spleen, but not blood, it was hypothesized that ZAP-70 expression may correlate with the activation level of the B cell. To address this issue, purified tonsillar B cells were sorted into CD38
Hi and CD38
Low populations (Figure 3a) and assessed for ZAP-70 expression using two independent methods. The CD38 Hi B-cell subset expressed higher levels of cytoplasmic ZAP-70 than did the CD38 Low B-cell subset as revealed by flow cytometry (Figure 3b ) and immunoblot analysis (Figure 3c ). Of note, the immunoblot analysis provides an independent validation of the cytoplasmic staining methodology.
We next analyzed the expression levels of a variety of phenotypic markers on ZAP-70 þ vs ZAP-70À B cells. As can be seen in Figure 4 , ZAP-70 þ B cells express a higher level of CD38 than do ZAP-70À B cells, adding further support to the conclusions drawn from the data shown in Figure 3 . CD20 was highly expressed on these cells, again confirming that these ZAP-70 þ cells are indeed B-lineage cells. ZAP-70 þ B cells consisted of both surface IgM þ and IgG þ cells, expressed a variable level of CD5, and expressed somewhat higher levels of CD27 than did ZAP-70À B cells. Lastly, ZAP-70 þ B cells do not express CD138, suggesting that these cells are not plasma cells. This observation is further supported by our failure to detect ZAP-70 expression in four human myeloma cell lines (data not shown). 
ZAP-70 is rapidly phosphorylated upon BCR stimulation
ZAP-70 expression can be induced in B cells
The data described above indicate that ZAP-70 expression is largely restricted to cells expressing an activated cell phenotype. We next wished to determine whether ZAP-70 expression levels could be induced or further increased. When peripheral blood B cells or tonsillar B cells were purified and stimulated with CD40L þ IL-10, IL-4, and IL-6, the cells showed an increased level of ZAP-70 expression compared to unstimulated cells cultured in RPMI and 5% FCS as shown by immunoblot. In addition, polyclonal stimulation using CpG ODN 2006 with IL-15 also resulted in increased levels of ZAP-70 ( Figure 6 ).
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Discussion
In this report, we present clear evidence that normal human B-lineage cells can indeed express ZAP-70. Our observations that a fraction of ZAP-70 þ B cells are present in tonsil and spleen, but not in peripheral blood, suggest that ZAP-70 expression may be restricted to a specific B-cell subpopulation or reflects B-cell activation status. Thus, tonsil and spleen are tissues where activated B cells would normally be found, in contrast to peripheral blood, which largely consists of resting cells. We also show for the first time that BCR crosslinking of normal human B cells results in tyrosine phosphorylation of ZAP-70.
Our observations are germane to recent reports demonstrating the prognostic value of ZAP-70 expression in B-CLL patients. One of the goals of our study was to assess whether B-CLL ZAP-70 expression was aberrant and secondary to transformation. Of note, two recent reports suggest that ZAP-70 may also be expressed in other types of B-cell malignancies such as nonHodgkin's lymphoma. 19, 26 Our observations are consistent with and further predict that ZAP-70 expression would not be restricted to B-CLL. Although our results do not formally disprove that ZAP-70 expression is deregulated during transformation, our results demonstrating normal B-cell ZAP-70 expression, particularly in B cells displaying a more activated phenotype, suggest that ZAP-70 þ B-CLL cells may likewise express a more activated phenotype than do their ZAP-70À B-CLL counterparts. Of interest, using global gene expression profiling, Rosenwald et al 8 were the first to show that many of the genes that were more highly expressed in Ig-unmutated CLL were induced during activation of normal blood B cells. These observations prompted the authors to suggest that this subset of B-CLL bears a more activated phenotype and may reflect ongoing in vivo stimulation, thereby explaining the more aggressive disease course observed in these patients. This concept has received additional confirmation from follow-up work published by Chen et al, 17, 18 demonstrating that the expression of ZAP-70 is associated with increased BCR signaling in this disease. In this report, these authors further suggest that global tyrosine phosphorylation is increased in ZAP-70 þ cells. Although this is an interesting concept, others have shown that ZAP-70 has a 100-fold lower effector function than Syk. 27 Therefore, it is unlikely that an increase in ZAP-70 expression actually directly affects this enhanced ability of B-cell signaling. A rigorous elucidation of the role of ZAP-70 in mature human B cells will be required to distinguish among these possibilities.
Although our studies clearly show that ZAP-70-expressing B cells are present in freshly isolated tonsil or spleen cells, polyclonal activation was required to induce ZAP-70 expression in peripheral blood B cells. The latter observation is interesting because Chan et al 3 have previously reported that ZAP-70 expression is not upregulated after polyclonal T-cell activation. Although ZAP-70 expression appeared to be restricted to B cells bearing a more activated phenotype, our data also demonstrate that not all activated B cells express ZAP-70 at high levels. These observations support the hypothesis that ZAP-70 expression may not be a hallmark feature of all activated B cells, but rather may only be expressed by a specific subpopulation of B cells. Preliminary data that we have generated also indicates that ZAP-70 expression in B-CLL cells may modulate with in vitro stimulation (JCN and DFJ, unpublished results), adding further support for a role for ZAP-70 in B-cell activation. One can therefore hypothesize that the expression of ZAP-70 in CLL patients may not be the result of the transformation, but alternatively caused by enhanced in vivo stimulation.
It is interesting to note that ZAP-70 expression in normal B cells was observed at higher levels in CD38 þ B cells. CD38 expression also has prognostic value in B-CLL, with higher expression levels observed in patients with more aggressive disease. 10, 12, 28, 29 Although Zupo et al 30 have shown that CD38-expressing B cells appeared to be more responsive to BCR ligation, thereby supporting a potential link between CD38 and ZAP-70 expression, Chen et al 17 failed to observe a statistically significant correlation between expression of these two genes in B-CLL. Nonetheless, a correlation may exist between CD38 expression and ZAP-70 expression in normal B cells. Additional studies are required to test this hypothesis.
Although Syk and ZAP-70 are strikingly similar at both the structural and functional level, it is important to highlight the functional differences between these Src kinases (reviewed in Latour and Veillette 31 ). Thus, activation of ZAP-70 requires phosphorylation by other Src family kinases, whereas this is not required by Syk. 32 There is also evidence that the binding of the Syk SH2 domains to ITAMs is distinct from that of ZAP-70. 33 Steinberg et al 34 have recently demonstrated that ZAP-70 is superior to Syk with regard to TCR-z phosphorylation and association, further supporting functional differences between the two kinases.
Another striking difference between Syk and ZAP-70 was shown by Latour et al 35 in the same report demonstrating the superior enzymatic activity of Syk. In this regard, it was also shown that Syk had the capacity to phosphorylate c-Cbl, a suspected negative regulator of immunoreceptor signaling. However, ZAP-70 was unable to perform this function. Thymocytes from c-Cbl-deficient mice exhibited an overall increase in ZAP-70 activity and tyrosine phosphorylation of downstream signaling components. 36 However, in a c-Cbldeficient B-cell line (DT40), it has been shown that the increased BCR response does not result from an increase in Syk activity, but rather from an increased level of association between the adaptor molecule BLNK and PLC-g2. 37 It was therefore proposed that the role of c-Cbl in B cells is to bind BLNK and prevent recruitment of PLC-g2. Therefore, it can be speculated that the expression of ZAP-70 in B cells may allow occupancy of c-Cbl, thereby preventing negative regulation in a highly activated B cell.
In conclusion, our data clearly demonstrate the expression of ZAP-70 in a subset of B cells that expresses a phenotype consistent with an activated cell. However, no evidence has yet to be shown that demonstrates a purpose for ZAP-70 in either normal or leukemic B cells other than the same function provided by the other family member, Syk. Perhaps, ZAP-70 plays a different, more specific role in B-cell development other than what has been shown.
